References: Liver Enzymes and Non-Alcoholic Fatty Liver Disease: Important Factors in Assessing Patterns of Clinical Management in Type-2 Diabetes Patients [Letter]

138

Views

CrossRef citations to date

Altmetric

References

Bideberi AT, Mutagaywa R. Statin prescription patterns and associated factors among patients with Type 2 diabetes mellitus attending diabetic clinic at Muhimbili National Hospital, Dar Es Salaam, Tanzania. Diabetes, Metab Syndr Obes Targets Ther. 2022;15:633–646. doi:10.2147/DMSO.S347765
Web of Science ®Google Scholar
Glinghammar B, Rafter I, Lindström AK, et al. Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma. Int J Mol Med. 2009;23(5):621–631. doi:10.3892/ijmm_00000173
PubMed Web of Science ®Google Scholar
Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity. 2008;16(6):1394–1399. doi:10.1038/oby.2008.64
Web of Science ®Google Scholar
Lazo M, Rubin J, Clark JM, et al. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol. 2015;62(4):841–847. doi:10.1016/j.jhep.2014.11.024
Web of Science ®Google Scholar
Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212–1218. doi:10.2337/dc06-2247
PubMed Web of Science ®Google Scholar